Compounds > methasquin
Page last updated: 2024-12-06

methasquin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

methasquin: folic acid antagonist that has been used in the treatment of experimental leukemia; acts by inhibiting the dihydrofolate reductase in the cell; minor descriptor (75-85); on-line & Index Medicus search ASPARTIC ACID/AA (75-85); RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID29335
CHEMBL ID154418
MeSH IDM0262979

Synonyms (7)

Synonym
aspartic acid,4-diamino-5-methyl-6-quinazolinyl)methyl]amino] benzoyl]-, l-
l-aspartic acid,4-diamino-5-methyl-6-quinazolinyl)methyl]amino] benzoyl]-,
methasquin
2-[[4-[(2,4-diamino-5-methyl-quinazolin-6-yl)methylamino]benzoyl]amino]butanedioic acid
nsc122870
l-aspartic acid, n-[4-[[(2,4-diamino-5-methyl-6-quinazolinyl)methyl]-
CHEMBL154418
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1123092Inhibition of thymidylate synthetase in Lactobacillus casei1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
AID1123091Inhibition of thymidylate synthetase in mouse L1210S cells1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
AID1123094Inhibition of dihydrofolate reductase in mouse L1210R cells1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
AID56152Binding energy against Streptococcus faecium dihydrofolate reductase1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors.
AID1146760Inhibition of Streptococcus faecium dihydrofolate reductase using dihydrofolate as substrate1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.
AID56148Binding energy to Streptococcus faecium dihydrofolate reductase1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Quantitative structure-activity relationship by distance geometry: quinazolines as dihydrofolate reductase inhibitors.
AID1123093Inhibition of dihydrofolate reductase in human acute lymphocytic leukemia cells1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrimethamine
Maloprim: contains above 2 cpds		1.9610aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		1.9510aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		1.9510
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.3620aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		1.9610adamantanes;
polycyclic alkane
diaveridine
diaveridine: RN given refers to parent cpd; structure. diaveridine : An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species.		1.9510aminopyrimidineantiparasitic agent;
drug allergen
metoprine
metoprine: histamine methyltransferase antagonist		1.9610
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		1.9610
2,4-diamino-5-adamantyl-6-methylpyrimidine
[no description available]		1.9610
2,4-diamino-5-benzylpyrimidine
2,4-diamino-5-benzylpyrimidine: structure given in first source		1.9510
pam 1392
[no description available]		1.9510
wr 158122
WR 158122: structure		2.6530
cb 3703
CB 3703: inhibitor of dihydrofolate reductase & thymidylate synthetase; RN given refers to parent cpd		1.9510
wr 159412
[no description available]		2.6530
methotrexate
[no description available]		7.3620dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
nitroquine
nitroquine: RN given refers to parent cpd		1.9510
(5)n,(8)n-deaza-(10)-n-methylfolate
[no description available]		2.8740
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9510
Leukemia, Lymphocytic
[description not available]		01.9510
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9510